ADC Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat ADC Therapeutics de winst en omzet met respectievelijk 24.1% en 33.3% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 35.1% per jaar.

Belangrijke informatie

24.1%

Groei van de winst

35.1%

Groei van de winst per aandeel

Biotechs winstgroei	27.1%
Inkomstengroei	33.3%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	01 Nov 2024

Recente toekomstige groei-updates

Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter Results

May 10

Recent updates

ADC Therapeutics SA (NYSE:ADCT) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Jul 18

Limiting Concerns On ADC Therapeutics' Prospects

Jun 06

ADC Therapeutics SA's (NYSE:ADCT) 26% Dip In Price Shows Sentiment Is Matching Revenues

May 30

Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter Results

May 10

ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)

Mar 19

ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues

Mar 17

ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth

Jan 18

ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial

Dec 29

An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued

Dec 14

Analysts Have Just Cut Their ADC Therapeutics SA (NYSE:ADCT) Revenue Estimates By 28%

May 11

ADC Therapeutics SA's (NYSE:ADCT) Shares Lagging The Industry But So Is The Business

Apr 18

ADC Therapeutics stock slips after pricing stock offering by seller

Feb 02

Does ADC Therapeutics (NYSE:ADCT) Have A Healthy Balance Sheet?

Jan 16

Jose Carmona joins ADC Therapeutics as CFO

Dec 19

ADC Therapeutics Non-GAAP EPS of $0.13, revenue of $76.32M

Nov 08

ADC, Sobi Zynlonta for blood cancer subtype gets EMA panel backing for EU approval

Sep 16

ADC Therapeutics gets downgraded at Morgan Stanley, price target cut to $11

Sep 09

ADC Therapeutics Non-GAAP EPS of -$0.73, revenue of $17.29M misses by $13.93M

Aug 09

Winst- en omzetgroeiprognoses

NYSE:ADCT - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	117	-151	-107	-245	5
12/31/2025	85	-166	-100	-169	6
12/31/2024	73	-162	-68	-147	6
6/30/2024	67	-215	-147	-145	N/A
3/31/2024	69	-227	-150	-147	N/A
12/31/2023	70	-240	-122	-119	N/A
9/30/2023	123	-182	-139	-138	N/A
6/30/2023	184	-184	-103	-102	N/A
3/31/2023	182	-200	-120	-120	N/A
12/31/2022	210	-157	-139	-138	N/A
9/30/2022	157	-166	-149	-146	N/A
6/30/2022	94	-187	-212	-207	N/A
3/31/2022	80	-195	-219	-212	N/A
12/31/2021	34	-230	-240	-233	N/A
9/30/2021	17	-252	-230	-223	N/A
6/30/2021	4	-200	-215	-209	N/A
3/31/2021	N/A	-254	-195	-192	N/A
12/31/2020	N/A	-246	-172	-169	N/A
9/30/2020	N/A	-226	-153	-151	N/A
6/30/2020	N/A	-237	-140	-139	N/A
3/31/2020	1	-135	-128	-126	N/A
12/31/2019	2	-116	-124	-122	N/A
9/30/2019	3	-112	-121	-118	N/A
6/30/2019	3	-111	-119	-116	N/A
3/31/2019	2	-117	-122	-118	N/A
12/31/2018	1	-123	-124	-121	N/A
12/31/2017	2	-90	N/A	-75	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat ADCT de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat ADCT de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat ADCT de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van ADCT ( 33.3% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van ADCT ( 33.3% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van ADCT naar verwachting over 3 jaar hoog zal zijn

ADC Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates upgraded to US$1.84 loss, revenue downgraded

Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter Results

Consensus EPS estimates fall by 13%, revenue upgraded

Price target increased by 19% to US$10.50

Price target increased by 12% to US$8.80

Consensus revenue estimates fall by 11%

Recent updates

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

ADC Therapeutics SA has filed a Follow-on Equity Offering in the amount of $100 million.

ADC Therapeutics SA (NYSE:ADCT) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Limiting Concerns On ADC Therapeutics' Prospects

ADC Therapeutics SA's (NYSE:ADCT) 26% Dip In Price Shows Sentiment Is Matching Revenues

Consensus EPS estimates upgraded to US$1.84 loss, revenue downgraded

CEO & Director recently sold US$133k worth of stock

Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter Results

ADC Therapeutics SA has completed a Follow-on Equity Offering in the amount of $105 million.

ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma

First quarter 2024 earnings: Revenues and EPS in line with analyst expectations

ADC Therapeutics SA has filed a Follow-on Equity Offering.

ADC Therapeutics SA, Annual General Meeting, Jun 13, 2024

Consensus EPS estimates fall by 13%, revenue upgraded

ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)

ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues

New minor risk - Shareholder dilution

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth

ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards

ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial

An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued

ADC Therapeutics: Navigating A Swirling Drain

New major risk - Share price stability

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

Price target increased by 19% to US$10.50

Price target increased by 12% to US$8.80

New major risk - Share price stability

Consensus revenue estimates fall by 11%

ADC Therapeutics SA Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs At the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)

ADC Therapeutics: Slowly Moving Toward Solvency

New major risk - Negative shareholders equity

Consensus revenue estimates decrease by 20%, EPS upgraded

New major risk - Negative shareholders equity

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

ADC Therapeutics SA to Report Q2, 2023 Results on Aug 08, 2023

China National Medical Products Administration Accepts Biologics License Application and Grants Priority Review for ZYNLONTA for Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

ADC Therapeutics SA Announces Voluntary Pause in the Enrollment of New Patients in the Phase 2 LOTIS-9 Clinical Trial Evaluating ZYNLONTA

Now 31% undervalued after recent price drop

Are Investors Undervaluing ADC Therapeutics SA (NYSE:ADCT) By 32%?

High number of new directors

Price target decreased by 18% to US$9.33

ADC Therapeutics SA Announces Evolution of Board of Directors

ADC Therapeutics SA Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA(R) in Relapsed/Refractory DLBCL

ADC Therapeutics: Maybe A 2024 Story

Consensus revenue estimates decrease by 28%, EPS upgraded

Price target increased by 9.4% to US$12.40

Consensus revenue estimates decrease by 29%, EPS upgraded

ADC Therapeutics SA Announces Updated Results from LOTIS-2 Trial to Be Presented at the European Hematology Association 2023 Hybrid Congress

Analysts Have Just Cut Their ADC Therapeutics SA (NYSE:ADCT) Revenue Estimates By 28%

ADC Therapeutics SA, Annual General Meeting, Jun 14, 2023

Price target increased by 8.5% to US$13.20

Price target increased by 7.4% to US$13.20

ADC Therapeutics SA's (NYSE:ADCT) Shares Lagging The Industry But So Is The Business

Consensus revenue estimates fall by 16%

Price target decreased by 15% to US$11.14

Price target decreased by 8.5% to US$12.29

ADC Therapeutics SA has completed a Follow-on Equity Offering in the amount of $60 million.

ADC Therapeutics stock slips after pricing stock offering by seller

Does ADC Therapeutics (NYSE:ADCT) Have A Healthy Balance Sheet?

ADC Therapeutics SA Announces Executive Changes

ADC Therapeutics SA and Swedish Orphan Biovitrum AB Announce the European Commission Approval of Zynlonta® (Loncastuximab Tesirine)

ADC Therapeutics Sa Appoints Jose Carmona as Chief Financial Officer

Jose Carmona joins ADC Therapeutics as CFO

Price target decreased to US$14.17

High number of new directors

Price target decreased to US$14.83

Price target increased to US$19.20